Ampicillin STADA Nordic: Uses, Dosage & Side Effects

What Is Ampicillin STADA Nordic and What Is It Used For?

Ampicillin is a broad-spectrum, semi-synthetic aminopenicillin antibiotic that was first introduced into clinical practice in 1961. It was the first penicillin with meaningful activity against Gram-negative bacteria, representing a significant advance over earlier penicillins such as benzylpenicillin (penicillin G) which were primarily effective against Gram-positive organisms. Ampicillin STADA Nordic is a branded formulation of ampicillin sodium, supplied as a sterile powder for reconstitution into a solution for injection or infusion. It is manufactured by STADA Arzneimittel AG and is indicated for use in clinical settings where parenteral antibiotic therapy is required.

The medication works through a bactericidal mechanism of action: it inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls by binding to penicillin-binding proteins (PBPs). These enzymes are critical for the cross-linking of peptidoglycan chains, which provide structural rigidity and osmotic stability to bacterial cell walls. When ampicillin binds to and inactivates PBPs, the cell wall becomes structurally compromised. Combined with the continued activity of autolytic enzymes (autolysins) within the bacterium, this leads to cell wall degradation, osmotic lysis, and bacterial death. Human cells lack peptidoglycan cell walls, which accounts for the selective toxicity of ampicillin against bacteria with relatively limited effects on host tissues.

Ampicillin has a broad spectrum of antibacterial activity encompassing both Gram-positive and Gram-negative organisms. Key susceptible pathogens include Streptococcus pneumoniae, Streptococcus pyogenes (Group A streptococcus), Streptococcus agalactiae (Group B streptococcus), Enterococcus faecalis, Listeria monocytogenes, Haemophilus influenzae (non-beta-lactamase producing), Escherichia coli (non-beta-lactamase producing), Proteus mirabilis, Salmonella species, and Neisseria meningitidis. However, resistance to ampicillin has become increasingly prevalent, particularly among Gram-negative bacteria that produce beta-lactamase enzymes capable of hydrolyzing the beta-lactam ring. For this reason, ampicillin is frequently combined with a beta-lactamase inhibitor such as sulbactam (sold as ampicillin/sulbactam) to extend its spectrum of activity.

When administered intravenously, ampicillin achieves rapid and high plasma concentrations, making it suitable for the treatment of severe and life-threatening infections. It distributes widely into body tissues and fluids, including cerebrospinal fluid when the meninges are inflamed, which is of particular importance in the treatment of bacterial meningitis. The plasma half-life of ampicillin is approximately 1 hour in adults with normal renal function, necessitating frequent dosing (typically every 4–6 hours) to maintain therapeutic concentrations.

The clinical indications for parenteral ampicillin include a wide range of serious infections:

• Bacterial meningitis: Ampicillin is a first-line agent for meningitis caused by Listeria monocytogenes and is used as part of empiric meningitis treatment regimens, particularly in neonates and patients over 50 years of age where listeria coverage is required.
• Infective endocarditis: Ampicillin, often in combination with an aminoglycoside (gentamicin), is a standard treatment for native valve endocarditis caused by Enterococcus faecalis and is also used in combination regimens for streptococcal endocarditis.
• Septicemia and bacteremia: Parenteral ampicillin is used as empiric and directed therapy for bloodstream infections caused by susceptible organisms, particularly enterococcal and listerial bacteremia.
• Respiratory tract infections: Severe community-acquired pneumonia, hospital-acquired pneumonia, lung abscess, and empyema caused by susceptible organisms may be treated with intravenous ampicillin.
• Urinary tract infections: Complicated upper urinary tract infections (pyelonephritis) and urosepsis caused by susceptible enterococci or other susceptible organisms.
• Gastrointestinal infections: Typhoid and paratyphoid fever (where susceptibility is confirmed), peritonitis, and biliary tract infections.
• Neonatal infections: Ampicillin is a cornerstone of empiric neonatal sepsis treatment, typically combined with an aminoglycoside, providing coverage against Group B streptococcus, Listeria monocytogenes, and susceptible E. coli.
• Intrapartum prophylaxis: Intravenous ampicillin is the first-line agent for Group B Streptococcus (GBS) prophylaxis during labor to prevent early-onset neonatal GBS disease.
• Surgical prophylaxis: Preoperative ampicillin may be used for certain gastrointestinal, biliary, and genitourinary surgical procedures to prevent postoperative infection.

Ampicillin is included on the World Health Organization (WHO) Model List of Essential Medicines, classified as an Access antibiotic under the WHO AWaRe (Access, Watch, Reserve) classification system. This designation underscores its importance as a first-line treatment option that should be widely available while being used responsibly to minimize the emergence and spread of antimicrobial resistance. Despite the development of newer antibiotics, ampicillin remains irreplaceable for certain clinical indications, particularly listeria infections and enterococcal endocarditis, where few alternative agents offer equivalent efficacy.

What Should You Know Before Taking Ampicillin STADA Nordic?

Contraindications

Ampicillin STADA Nordic must not be administered to patients with a confirmed hypersensitivity to ampicillin, any other penicillin antibiotic, or any of the excipients in the formulation. A history of a severe allergic reaction (such as anaphylaxis, angioedema, or Stevens-Johnson syndrome) to any beta-lactam antibiotic is an absolute contraindication. Penicillin allergy is one of the most commonly reported drug allergies, affecting approximately 8–10% of the general population, although studies have shown that up to 90% of patients labeled as penicillin-allergic can actually tolerate penicillins after formal evaluation. Nevertheless, the consequences of administering a penicillin to a truly allergic patient can be severe and potentially fatal.

Cross-reactivity between penicillins and cephalosporins has historically been estimated at 5–10%, although more recent data suggest the true cross-reactivity rate is closer to 1–2%, primarily involving first-generation cephalosporins with similar side-chain structures. Patients with a history of immediate-type hypersensitivity (urticaria, angioedema, anaphylaxis) to any penicillin should not receive ampicillin unless they have undergone formal allergy evaluation and penicillin skin testing. Carbapenem antibiotics share the beta-lactam ring structure but have a very low cross-reactivity rate with penicillins (less than 1%), and may be considered as alternatives in many clinical situations after appropriate risk assessment.

Ampicillin should also not be administered to patients with infectious mononucleosis (glandular fever) or lymphocytic leukemia, as these conditions are associated with a very high incidence (60–100%) of developing a widespread, non-allergic maculopapular rash upon exposure to aminopenicillins. While this rash is generally not a true allergic reaction, it can be severe and difficult to distinguish from a genuine drug allergy, complicating future antibiotic decisions.

Warnings and Precautions

Before initiating ampicillin therapy, healthcare providers should carefully evaluate the patient's medical history with attention to several key areas. Patients should be specifically questioned about any prior allergic reactions to antibiotics, particularly penicillins, cephalosporins, and carbapenems. Even mild previous reactions should be documented and considered, as subsequent exposures can sometimes provoke more severe responses.

Patients with impaired renal function require dose adjustments, as ampicillin is primarily eliminated by the kidneys. In patients with a creatinine clearance below 10–30 mL/min, the dosing interval should be extended or the dose reduced to prevent drug accumulation and the increased risk of neurotoxicity (seizures) and other adverse effects. Ampicillin is removed by hemodialysis, and supplemental doses should be given after dialysis sessions.

Prolonged use of ampicillin, like all antibiotics, can lead to the overgrowth of non-susceptible organisms, including fungi (particularly Candida species) and resistant bacteria. Patients should be monitored for signs of superinfection during treatment, and appropriate measures should be taken if superinfection occurs. Of particular concern is Clostridioides difficile-associated diarrhea (CDAD), which can range from mild diarrhea to severe pseudomembranous colitis. CDAD has been reported with the use of nearly all antibacterial agents, including ampicillin, and may occur during treatment or even several weeks after treatment has been discontinued. If CDAD is suspected or confirmed, ongoing antibiotic therapy not directed against C. difficile should be discontinued if possible.

High doses of intravenous ampicillin, particularly when administered as rapid bolus injections, have been associated with seizures, especially in patients with renal impairment, a history of seizure disorders, or those receiving meningeal doses. Intravenous doses should be administered slowly over at least 3–5 minutes for direct injection, or over 15–30 minutes as an infusion, to minimize this risk.

Pregnancy and Breastfeeding

Ampicillin is generally considered safe for use during pregnancy and is one of the most extensively studied and commonly used antibiotics in obstetric practice. It crosses the placenta and reaches the fetal circulation, but extensive clinical experience spanning several decades has not demonstrated an increased risk of congenital malformations or adverse fetal outcomes when used at therapeutic doses. Ampicillin is classified as a former FDA Pregnancy Category B drug, indicating that animal reproduction studies have not demonstrated fetal risk and there are no adequate and well-controlled studies in pregnant women, but clinical experience supports its safety.

Intravenous ampicillin plays a critical role in obstetric care, particularly as the first-line agent for intrapartum antibiotic prophylaxis (IAP) against Group B Streptococcus (GBS) colonization. GBS is the leading cause of early-onset neonatal sepsis and meningitis in many countries, and maternal intrapartum prophylaxis with intravenous ampicillin or penicillin G has been shown to reduce early-onset GBS disease by approximately 80%. Ampicillin is also used to treat chorioamnionitis (intra-amniotic infection), pyelonephritis in pregnancy, and other serious maternal infections.

Ampicillin is excreted into breast milk in small quantities. While this could theoretically cause sensitization, diarrhea, or candidiasis in the nursing infant, ampicillin is generally considered compatible with breastfeeding by major guidelines including those from the American Academy of Pediatrics and LactMed. The amount of drug reaching the infant through breast milk is very small compared to therapeutic pediatric doses, and significant adverse effects in breastfed infants are uncommon. Nevertheless, nursing mothers should be advised to monitor their infants for signs of gastrointestinal disturbance (diarrhea, thrush) during maternal ampicillin therapy.

How Does Ampicillin STADA Nordic Interact with Other Drugs?

Drug interactions with ampicillin can affect its efficacy, increase the risk of adverse effects, or alter the pharmacokinetics of concomitant medications. Healthcare providers should review all current medications before initiating ampicillin therapy. The most clinically significant interactions are summarized below.

Major Interactions

Minor Interactions

Additionally, ampicillin can interfere with certain laboratory tests. It may cause false-positive results in urine glucose tests that use the copper-reduction method (such as Clinitest) but does not affect glucose oxidase-based tests (such as Clinistix or Diastix). Ampicillin can also interfere with the Direct Coombs test, producing false-positive results, which is important to consider in transfusion medicine and neonatal screening. High concentrations of ampicillin in urine specimens may also produce false-positive results for protein using certain colorimetric assays.

What Is the Correct Dosage of Ampicillin STADA Nordic?

Ampicillin STADA Nordic is available as a powder for reconstitution containing 1 g of ampicillin (as ampicillin sodium). The reconstituted solution can be administered by slow intravenous injection (over 3–5 minutes), intravenous infusion (over 15–30 minutes), or deep intramuscular injection. The choice of route and the specific dose depend on the site and severity of infection, the suspected or confirmed causative organism, and patient-specific factors including age, body weight, and renal function.

Adults

Children

Pediatric dosing of ampicillin is based on body weight. The recommended dose varies significantly depending on the severity and type of infection. Ampicillin is one of the most commonly used parenteral antibiotics in neonatal and pediatric intensive care, and accurate weight-based dosing is essential to ensure both efficacy and safety.

Elderly

No specific dose adjustment is required for elderly patients solely on the basis of age. However, elderly patients are more likely to have impaired renal function, and dose adjustments based on creatinine clearance should be made as appropriate. Elderly patients may also be more susceptible to certain adverse effects, including Clostridioides difficile infection and electrolyte disturbances (hypernatremia with high-dose sodium-containing formulations). Renal function should be monitored regularly during treatment, particularly with prolonged or high-dose therapy.

Dose Adjustment in Renal Impairment

Missed Dose

In clinical settings, ampicillin is administered by healthcare professionals on a strict schedule. If a dose is inadvertently delayed, it should be given as soon as possible, and the subsequent dose schedule should be adjusted accordingly to maintain appropriate dosing intervals. It is important not to double-dose to compensate for a missed administration. In critical infections such as meningitis and endocarditis, maintaining consistent therapeutic drug levels is paramount, and missed doses should be reported to the supervising physician immediately so that the treatment plan can be reassessed.

Overdose

Ampicillin has a wide therapeutic index, and significant toxicity from overdose is uncommon. However, very high doses, particularly in patients with impaired renal function, can lead to neurotoxicity manifesting as seizures, encephalopathy, and altered consciousness. Excessive intravenous doses may also cause electrolyte imbalances due to the sodium content of ampicillin sodium (each gram contains approximately 2.7 mmol of sodium). Management of overdose is supportive and symptomatic. Ampicillin can be removed by hemodialysis if clinically indicated. In cases of seizure activity, benzodiazepines (such as diazepam or lorazepam) should be administered as first-line anticonvulsant therapy.

What Are the Side Effects of Ampicillin STADA Nordic?

Like all medications, ampicillin can cause side effects, although not everyone who receives it will experience them. The frequency and severity of adverse reactions depend on the dose, duration of treatment, route of administration, and individual patient factors. Below is a comprehensive overview of known side effects organized by frequency according to the internationally recognized classification (MedDRA/CIOMS).

The gastrointestinal side effects of ampicillin (diarrhea, nausea, abdominal discomfort) are generally mild and self-limiting, resolving after treatment completion. Diarrhea occurs more frequently with ampicillin than with amoxicillin due to differences in oral bioavailability and gut flora exposure, although with parenteral administration the incidence can still be significant as the drug is excreted in bile and reaches the intestinal lumen. Patients should be encouraged to maintain adequate hydration and should report any severe, persistent, or bloody diarrhea to their healthcare team promptly, as this may indicate Clostridioides difficile infection requiring specific treatment.

Allergic reactions to ampicillin range from mild skin rashes (occurring in approximately 3–10% of patients) to severe, life-threatening anaphylaxis (estimated at 1–5 per 10,000 treatment courses). It is important to distinguish between a true immunologically mediated allergic rash (typically urticarial, occurring within hours to days of starting treatment) and the characteristic non-allergic ampicillin rash (a diffuse, symmetrical, maculopapular eruption that typically appears 5–14 days after initiating therapy). The latter is particularly common in patients with concurrent Epstein-Barr virus infection (infectious mononucleosis), cytomegalovirus infection, acute lymphocytic leukemia, and hyperuricemia treated with allopurinol. This non-allergic rash does not necessarily preclude future use of penicillins, although formal allergy evaluation may be warranted.

How Should You Store Ampicillin STADA Nordic?

Proper storage of Ampicillin STADA Nordic is essential to maintain the potency and sterility of the product. The unreconstituted powder for injection/infusion should be stored in its original packaging at a temperature not exceeding 25°C (77°F). The vials should be protected from direct light and moisture. As with all pharmaceutical products, ampicillin should be stored out of the reach and sight of children.

Once reconstituted with an appropriate diluent (typically Water for Injections or 0.9% Sodium Chloride solution), the stability of the ampicillin solution is limited. From a chemical and physical stability perspective, reconstituted ampicillin solutions should ideally be used immediately after preparation. If immediate use is not possible, in-use storage times and conditions are the responsibility of the user and should generally not exceed 1 hour at room temperature (25°C) for solutions in Water for Injections, or up to 8 hours when refrigerated at 2–8°C, depending on the specific formulation and concentration. Solutions prepared in 0.9% Sodium Chloride for infusion should be used within 4 hours of preparation at room temperature. Ampicillin solutions should not be frozen.

Ampicillin is chemically unstable in glucose-containing solutions, and significant degradation can occur within hours. For this reason, ampicillin should not be added to glucose (dextrose) infusions unless it will be administered within 1 hour of preparation. The preferred diluent for intravenous infusion is 0.9% Sodium Chloride solution.

Before administration, the reconstituted solution should be visually inspected for particulate matter, discoloration, or precipitation. The solution should be clear to slightly yellow in color. Do not use if the solution is discolored, cloudy, or contains visible particles. Any unused solution remaining after administration should be discarded in accordance with local requirements for pharmaceutical waste disposal. Do not use Ampicillin STADA Nordic after the expiry date stated on the label and carton. The expiry date refers to the last day of that month.

What Does Ampicillin STADA Nordic Contain?

Ampicillin STADA Nordic is a minimally formulated injectable antibiotic product. Each vial contains ampicillin sodium equivalent to 1 g of ampicillin as the sole active substance. Ampicillin sodium is the sodium salt of the semi-synthetic penicillin ampicillin, which is derived from 6-aminopenicillanic acid (6-APA), the core structure shared by all penicillin antibiotics. The molecular formula of ampicillin sodium is C₁₆H₁₈N₃NaO₄S, and it has a molecular weight of approximately 371.4 daltons.

The powder is a white to off-white, hygroscopic (moisture-absorbing) crystalline substance that is freely soluble in water. Upon reconstitution with Water for Injections, it produces a clear to slightly yellow solution with a pH of approximately 8–10 (alkaline). Each gram of ampicillin sodium contains approximately 2.7 mmol (62 mg) of sodium, which should be considered in patients on sodium-restricted diets, particularly those receiving high doses or those with conditions such as congestive heart failure, hepatic cirrhosis, or severe renal impairment where sodium balance is critical.

Unlike many other injectable antibiotic formulations, Ampicillin STADA Nordic does not contain any preservatives, buffers, or other excipients. This is typical of many parenteral ampicillin products, as the sodium salt of ampicillin itself is sufficiently stable and soluble to allow reconstitution without the need for additional formulation components. The absence of preservatives means that the reconstituted solution should be used promptly after preparation, as there is no antimicrobial preservation system to prevent microbial contamination during extended storage.

The vials are made of clear Type I glass (which is resistant to alkaline solutions) with a bromobutyl rubber stopper and an aluminum seal with a flip-off cap. The packaging is designed to maintain the sterility and stability of the powder during its shelf life. Healthcare providers should check that the seal is intact before use and should not use vials that show signs of tampering or damage.